U.S. Markets closed

AstraZeneca PLC (AZN)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
29.12+0.04 (+0.14%)
At close: 4:02PM EDT
People also watch
Full screen
Previous Close29.08
Bid0.00 x 0
Ask0.00 x 0
Day's Range28.88 - 29.16
52 Week Range25.55 - 35.60
Avg. Volume4,906,581
Market Cap72.14B
PE Ratio (TTM)21.81
Earnings DateN/A
Dividend & Yield0.90 (3.09%)
Ex-Dividend Date2017-08-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com15 hours ago

    Tesaro: Losing Its Edge?

    The FDA decided yesterday to expand the use of the ovarian cancer drug Lynparza, sold by AstraZeneca (AZN) and Merck (MRK). The two drugs belong to a class known as PARP inhibitors. Approved in 2014, AstraZeneca's Lynparza was the first such drug to make its way through the FDA.

  • Barrons.com17 hours ago

    Ovarian Cancer Market Still Up For Grabs

    The Food and Drug Administration approved a broader label for AstraZeneca’s (AZN) breast cancer drug Lynparza to be used in ovarian cancer patients. Morgan Stanley’s Andrew Berens and his team are updating their models following the news, writing that he expects the three major players—AstraZeneca, Clovis Oncology (CLVS), and Tesaro (TSRO)—will likely split the market for second line (2L) treatment.

  • AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion
    Zacks23 hours ago

    AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion

    AstraZeneca, plc (AZN) and partner Merck's ovarian cancer drug, Lynparza has received FDA approval for new tablet formulation and a broader U.S. label.